The Antibacterial Effect of Chitosan Oligosaccharide and Its Derivative on Helicobacter pylori

被引：0

作者：

Lin Y. ^{[1
]}

Han Y. ^{[2
]}

Li H. ^{[3
]}

Jiang F. ^{[1
]}

Fu L. ^{[1
]}

Zhang Q. ^{[2
]}

Lin X. ^{[2
]}

机构：

[1] School of Pharmacy, SJTU, Shanghai

[2] Xiamen Bluebay Sci. Tech. Co., Ltd., Fujian, Xiamen

[3] 'Gastroenterology of the First Affiliated Hospital of Xiamen University, Fujian, Xiamen

来源：

Journal of Chinese Institute of Food Science and Technology | 2023年 / 23卷 / 06期

关键词：

chitosan oligosaccharide; Helicobacter pylori; hole method; inhibit concentration; metronidazole;

D O I：

10.16429/j.1009-7848.2023.06.008

中图分类号：

学科分类号：

摘要：

We use hole method to study the antibacterial effect of the chitosan and its derivative on Helicobacter pylori, the results shows that it can not generate antibacterial circle in different concentration of chitosan and carboxymethyl chitosan. Chitosan oligosaccharide B (degree of deacet ylation,DD=94%, 50mg/mL). has generated the antibacterial circle of Helicobacter pylori, the radius of bacteriostatic ring is (4.1-0.23) mm, while positive control (metronidazole, 10 mg/mL) is (5.5-0.15) mm. Chitosan oligosaccharide B (50 mg/mL) can vividly decrease the biological mass of Helicobacter pylori, while the chitosan oligosaccharide A (50 mg/mL) can not influence the growth of strain. Conclusion shows that chitosan oligosaccharide B (50 mg/mL) has the ability to restrain the Helicobacter pylori. The chitosan oligosaccharide A (deacetylation degree of 80%), chitosan and carboxymethyl chitosan provided in this experiment did not have the effect of inhibiting Helicobacter pylori. © 2023 Chinese Institute of Food Science and Technology. All rights reserved.

引用

页码：64 / 70

页数：6

共 23 条

[1] WU L M, JIANG J P., Research progress in the pathogenic mechanism of Helicobacter pylori and its treatment modalities, Health MedRes & Pra, 18, 4, pp. 144-148, (2021)
[2] ZAMANI M, EBRAHIMTABAR F, ZAMANI V, Et al., Systematic review with meta - analysis
[3] The worldwide of Helicobacter pylori infection, Aliment Pharmacol Ther, 47, 7, pp. 868-876, (2018)
[4] WANG W W, YAN Y., Research progress of heli-cobacter pylori infection, testing and drug develop-ment[J], Guangdong Chemical Industry, 49, 4, (2022)
[5] LI Y M, MA J, DUAN F L., ACG clinical guideline: treatment of Helicobacter pylori infection, Chin J Gastroenterol Hepatol, 26, 6, pp. 601-624, (2017)
[6] ZHOU X L, ZHOU Y, ZHU Q, Et al., Recent advance on Helicobacter pylori[J], China Continuing Medical Education, 10, 33, pp. 101-104, (2018)
[7] HU Y, ZHU Y, LU N H., Recent progress in Helicobacter pylori treatment, Chinese Medical Journal, 133, 3, pp. 335-343, (2020)
[8] GAO F, LIU T G, BAI C, Et al., The research of the correlation between brain-gut axis and gastrointestinal motility [J], Journal of Tianjin University of Traditional Chinese Medicine, 37, 6, pp. 520-524, (2018)
[9] BUSJAHN A, MEHLING H., Non-Viable Lactobacillus reuteri DSMZ 17648 (Pylopass1) as a New Approach to Helicobacter pylori Control in Humans, Nutrients, 5, 8, pp. 3062-3073, (2013)
[10] YANG H D, ZHANG X, SUVOROV A, Et al., Research progress of chitosan and chito oligosaccharide in bacteriostasis and preservation, Shandong Agricultural Sciences, 52, 2, (2020)

← 1 2 3 →